Article open access publication

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

British Journal of Cancer, Springer Nature, ISSN 0007-0920

Volume 110, 4, 2014

DOI:10.1038/bjc.2013.769, Dimensions: pub.1019315109, PMC: PMC3929867, PMID: 24548884,

Authors

Agarwal, D (1) (2)
Pineda, S (2)
Herranz, J (2) (4)
Pita, G (2)
Dennis, J (3)
Wang, Q (3)
Orr, N (9)
Jones, M (9)
Matsuo, K (10)
Ito, H (11)
Iwata, H (11)
Kondo, N (11)
Hartman, M (14) (15)
Hui, M (14) (15)
Lim, W Y (14) (15)
T-C Iau, P (14) (15)
Sawyer, E (16)
Tomlinson, I (17) (18)
Kerin, M (19)
Miller, N (19)
Kang, D (20)
Choi, J-Y (20)
Park, S K (20)
Noh, D-Y (20)
Makalic, E (21)
Teo, S H (22) (23)
Yip, C H (22)
Tay, W-T (15)
Brauch, H (24) (25)
Hamann, U (27)
The GENICA Network (24) (25) (26) (27) (28) (29) (30)
Shah, M (3)
Andrulis, I L (31) (32)
Knight, J A (31) (32)
Glendon, G (33)
Broeks, A (34)
Fasching, P A (35) (36)
Ekici, A B (37)
Shen, C-Y (38) (39)
Yu, J-C (40)
Hou, M-F (41)
Blot, W (42)
Cai, Q (42)
Wu, A H (43)
Tseng, C-C (43)
Stram, D O (43)
Cox, A (44)
Brock, I W (44)
Muir, K (19) (45)
Zheng, W (47)
Long, J (47)
Shu, X-O (47)
Lu, W (48)
Gao, Y-T (49)
Zhang, B (47)
Radice, P (50)
Mariette, F (51) (52)
McKay, J (54)
Couch, F J (55)
TNBCC (55)
Peto, J (58)
Marme, F (59) (60)
Burwinkel, B (27) (60)
Guénel, P (61) (62)
Truong, T (61) (62)
Sanchez, M (61) (62)
Mulot, C (62) (63)
Flyer, H (64)
Brenner, H (27)
Arndt, V (27)
Mannermaa, A (66) (67)
Kataja, V (66) (67)
Kosma, V-M (66) (67)
Hartikainen, J M (66) (67)
Floris, G (69)
Leunen, K (69)
Rudolph, A (27)
Seibold, P (27)
Wang, X (55)
Olson, J E (55)
Vachon, C (55)
Giles, G G (21) (70)
Severi, G (21) (70)
Baglietto, L (21) (70)
Simard, J (72)
Dumont, M (72)
Goldberg, M S (73) (74)
Pylkäs, K (76)
Grip, M (78)
Devilee, P (79)
Czene, K (8)
Darabi, H (8)
Kriege, M (80)
Li, J (84)
Durda, K (85)
Dörk, T (87)
Hall, P (8)
Zamora, P (7)
Milne, R L * (2) (21) (70)

* Corresponding author

Affiliations

Organisations

  1. (1) Yale University, grid.47100.32
  2. (2) Spanish National Cancer Research Centre, grid.7719.8
  3. (3) University of Cambridge, grid.5335.0
  4. (4) Madrid Institute for Advanced Studies, grid.429045.e
  5. (5) Cancer Research UK Cambridge Institute, grid.470869.4
  6. (6) Hospital Monte Naranco, grid.414858.4
  7. (7) Hospital Universitario La Paz, grid.81821.32
  8. (8) Karolinska Institute, grid.4714.6
  9. (9) Institute of Cancer Research, grid.18886.3f
  10. (10) Kyushu University, grid.177174.3
  11. (11) Aichi Cancer Center, grid.410800.d
  12. (12) Peter MacCallum Cancer Centre, grid.1055.1
  13. (13) QIMR Berghofer Institute of Medical Research, BrisbaneQueensland, Australia
  14. (14) National University Health System, grid.410759.e
  15. (15) National University of Singapore, grid.4280.e
  16. (16) King's College London, grid.13097.3c
  17. (17) University of Oxford, grid.4991.5
  18. (18) Wellcome Centre for Human Genetics, grid.270683.8
  19. (19) University of Warwick, grid.7372.1
  20. (20) Seoul National University, grid.31501.36
  21. (21) University of Melbourne, grid.1008.9
  22. (22) University Malaya Medical Centre, grid.413018.f
  23. (23) Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia
  24. (24) Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, grid.502798.1
  25. (25) University of Tübingen, grid.10392.39
  26. (26) Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr-University Bochum (IPA), Germany
  27. (27) German Cancer Research Center, grid.7497.d
  28. (28) Department of Internal Medicine, Evangelische Kliniken Bonn GmbH, Johanniter Krankenhaus, Bonn, Germany
  29. (29) Institute of Pathology, Medical Faculty of the University of Bonn, Germany
  30. (30) University Medical Center Hamburg-Eppendorf, grid.13648.38
  31. (31) University of Toronto, grid.17063.33
  32. (32) Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
  33. (33) Lunenfeld-Tanenbaum Research Institute, grid.250674.2
  34. (34) Antoni van Leeuwenhoek Hospital, grid.430814.a
  35. (35) University of California, Los Angeles, grid.19006.3e
  36. (36) Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
  37. (37) Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
  38. (38) China Medical University, grid.254145.3
  39. (39) Institute of Biomedical Sciences, Academia Sinica, grid.482251.8
  40. (40) Tri-Service General Hospital, grid.278244.f
  41. (41) Kaohsiung Medical University Chung-Ho Memorial Hospital, grid.412027.2
  42. (42) Vanderbilt University, grid.152326.1
  43. (43) University of Southern California, grid.42505.36
  44. (44) University of Sheffield, grid.11835.3e
  45. (45) University of Manchester, grid.5379.8
  46. (46) Ministry of Public Health, grid.415836.d
  47. (47) Vanderbilt University Medical Center, grid.412807.8
  48. (48) Shanghai Center for Disease Control and Prevention, Shanghai, China
  49. (49) Shanghai Cancer Institute, grid.419087.3
  50. (50) Fondazione IRCCS Istituto Nazionale dei Tumori, grid.417893.0
  51. (51) FIRC Institute of Molecular Oncology, grid.7678.e
  52. (52) Cogentech Cancer Genetic Test Laboratory, Milan, Italy
  53. (53) National Cancer Institute of Thailand, grid.419173.9
  54. (54) International Agency For Research On Cancer, grid.17703.32
  55. (55) Mayo Clinic, grid.66875.3a
  56. (56) The Ohio State University, grid.261331.4
  57. (57) National Centre of Scientific Research Demokritos, grid.6083.d
  58. (58) London School of Hygiene & Tropical Medicine, grid.8991.9
  59. (59) National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany
  60. (60) Heidelberg University, grid.7700.0
  61. (61) University of Paris-Sud, grid.5842.b
  62. (62) French Institute of Health and Medical Research, grid.7429.8
  63. (63) Centre de Ressources Biologiques EPIGENETEC, Paris, France
  64. (64) University of Copenhagen, grid.5254.6, KU
  65. (65) Krebsregister Saarland, grid.482902.5
  66. (66) Kuopio University Hospital, grid.410705.7
  67. (67) University of Eastern Finland, grid.9668.1
  68. (68) Flanders Institute for Biotechnology, grid.11486.3a
  69. (69) Universitair Ziekenhuis Leuven, grid.410569.f
  70. (70) Cancer Council Victoria, grid.3263.4
  71. (71) University of Hawaii at Manoa, grid.410445.0
  72. (72) Centre Hospitalier Universitaire de Québec, grid.411081.d
  73. (73) McGill University, grid.14709.3b
  74. (74) Royal Victoria Hospital, grid.416229.a
  75. (75) University of Montreal, grid.14848.31
  76. (76) Department of Clinical Chemistry and Biocenter Oulu, Laboratory of Cancer Genetics and Tumor Biology, University of Oulu, Oulu University Hospital, Oulu, Finland
  77. (77) Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland
  78. (78) Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland
  79. (79) Leiden University Medical Center, grid.10419.3d
  80. (80) Erasmus University Medical Center, grid.5645.2
  81. (81) Breast Cancer Now, grid.458394.7
  82. (82) National Cancer Institute, grid.48336.3a
  83. (83) Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, grid.418165.f
  84. (84) Genome Institute of Singapore, grid.418377.e
  85. (85) Pomeranian Medical University, grid.107950.a
  86. (86) Helsinki University Central Hospital, grid.15485.3d
  87. (87) Hannover Medical School, grid.10423.34

Description

BACKGROUND: Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. METHODS: Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. RESULTS: Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95% confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. CONCLUSION: Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2.

Funders

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Copenhagen

Dimensions Citation Indicators

Times Cited: 17

Field Citation Ratio (FCR): 3.53

Relative Citation ratio (RCR): 0.89

Open Access Info

Hybrid